Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

ts. The highest percentage of discontinuations were due to withdrawn consent or lost to follow-up (12 percent and 11 percent, respectively).

The most commonly reported treatment-emergent adverse events reported throughout the study (.10 percent) included decreased appetite, headache, upper respiratory tract infection, cough, pyrexia and decreased weight. Most (98 percent) adverse events were mild or moderate in severity and consistent with known effects of methylphenidate. Three serious adverse events were reported and all were considered unrelated to DAYTRANA use.

DAYTRANA Demonstrated Significant Improvements in ADHD-RS-IV, CGI-I and PGA Scores

In the study, the children experienced a significant overall mean reduction in their ADHD Rating Scale-IV (ADHD-RS-IV) total score. When the study began, the mean total score on the ADHD-RS-IV was 25.0. When using Daytrana, the mean ADHD-RS-IV total scores declined, with children averaging 15.4 at study end. The overall mean change in ADHD-RS-IV total score from study start to end was -9.3 (+/- 16.29) and was statistically significant (P<.0001). The total scores also declined significantly from study start to end on both the inattentiveness and hyperactivity/impulsivity ADHD-RS-IV subscales (P<.0001).

Investigators evaluated DAYTRANA's overall effectiveness using the Clinical Global Impressions-Improvement (CGI-I) and Parent Global Assessment (PGA) scales, both of which yielded significant ratings of improvement at study end, with 83 and 78 percent, respectively, reporting DAYTRANA "very much improved" or "much improved" the children's ADHD symptoms (P<.0001).

The study was supported by funding from Shire.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). ADHD is one of the mos
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:5/17/2013)... , May 17, 2013 Medical devices are ... a biological product. In light of their different mechanisms, ... are much more complicated than drug trails due to ... MD safety instead of evaluating both safety and efficacy ... FDA (which is the same as the SFDA) evaluate ...
(Date:5/17/2013)... DIEGO , May 17, 2013  Sorrento ... that its Fast-Track Advanced Technology Small Business Technology ... Institute of Allergy and Infectious Diseases (NIAID), a ... supporting the development of novel human antibody therapeutics ... aureus or Staph) infections, including methicillin-resistant ...
(Date:5/17/2013)... CHAPEL HILL, N.C. , May 17, 2013 ... on how organizations communicate internally. Faced with a ... adjust their strategies and tactics for communicating with ... the effectiveness of all the strategies, tactics and ... In a new study, Best ...
Breaking Medicine Technology:Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2
... a,biopharmaceutical company focused on the development of novel ... from its,Phase I safety and tolerability study of ... MRX-4 was nasally administered as a single ... first administration was given without a nasal,allergen challenge ...
... Applied,Biology, Inc. (FAB) announced today that it has ... IIB grant from the National,Science Foundation. The $500,000 ... cell-free protein synthesis technology towards commercialization., During ... Phase II,NSF projects, FAB successfully demonstrated that certain ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients 2Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology 2
(Date:5/20/2013)... 2013 VHA Inc., the national ... automated, provider-led population health improvement, announced a new ... and successfully pursue population health management with ... to accelerate the transition to value-based models of ... improvement suite of services, the offering integrates VHA ...
(Date:5/20/2013)... Washington, D.C., May 20, 2013 CosmosID, a leading data ... as part of a collaboration results on analysis of ... speed, specificity, and accuracy. , The Food and Drug ... number of commercially available probiotics, four of which have ... The purpose of the tests was to compare the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Finnish subjects and was led by Professor Samuli ... 28 genetic markers improved detection of individuals with ... risk ≥20%) over traditional risk factors. , Identification ... for CHD, because the current guidelines recommend statin ... that genetic markers could be useful in CHD ...
(Date:5/20/2013)... Dallas, TX (PRWEB) May 20, 2013 ... largest portfolio of employee benefit, payroll products and services ... announced that both are selected as finalists for the ... the Fastest-Growing Company of the Year category, and CompuPay ... Year. Each finalist will ultimately be a Gold, Silver ...
Breaking Medicine News(10 mins):Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
... , , ARLINGTON, ... Health and Human Services Office of Inspector General (OIG) ignored ... including complex rehab, to seniors and people with disabilities who ... the Medicare Program: Supplier Acquisition Costs and Services" and dated ...
... OKLAHOMA CITY, Sept. 3 Surgical Hospital of ... partnered with Surgical Care Affiliates (SCA), one of the country,s ... is a state of the art hospital providing surgical services ... pain management, podiatry and orthopedics. SCA and a number of ...
... done to protect young knees, ankles and shoulders, researcher says ... all high school sports injuries are bad enough to keep a ... the pack in severe injuries, a new U.S. study finds. , ... girls experienced a greater rate of severe injury than boys in ...
... worldunderstand and prepare for contagious outbreaks, the National Institutes ... adds new research expertise to increase its capacity to ... inform public health officials and policymakers. In ... and infected people around the world. In 2003, a ...
... delaying needed care ends up raising health-care costs, study ... -- Patients who don,t trust the health-care system are ... health and raising overall health care costs, a new ... majority of whom were black, about their attitudes toward ...
... , , , , ... entered into a definitive agreement under which Embla will acquire Covidien,s ... the Sandman(TM) brand name. Financial terms of the transaction were ... conditions. , , The combined entity will form ...
Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Surgical Hospital of Oklahoma to Partner with Surgical Care Affiliates 2Health News:High School Sports Put Players at Risk for Severe Injuries 2Health News:New grants expand US infectious disease modeling effort 2Health News:New grants expand US infectious disease modeling effort 3Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: